Carsten Schultz-Fademrecht

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignees: Bayer Intellectual Property Gmbh, Lead Discovery Center Gmbh, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2014-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carsten Schultz-Fademrecht. Retrieved from https://idiyas.com/inventor/carsten-schultz-fademrecht

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 57.1

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

3 out of 721

Bayer Intellectual Property Gmbh

patents

3 out of 15

Lead Discovery Center Gmbh

patents

1 out of 1,334

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

where one patent can have more than one assignee

Years Active: 2014-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10934274 - Quinoline derivatives as TAM RTK inhibitors (2021-03-02),

2. 9962389 - 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group (2018-05-08),

3. 9669034 - 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group (2017-06-06),

4. 9481668 - Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1 (2016-11-01),

5. 9096608 - Pharmaceutically active pyrazolo-triazine derivatives (2015-08-04),

6. 8999982 - Pharmaceutically active compounds as Axl inhibitors (2015-04-07),

7. 8916557 - Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines (2014-12-23),

Title: Carsten Schultz-Fademrecht: Innovator in Pharmaceutical Chemistry

Introduction

Carsten Schultz-Fademrecht is a notable inventor based in Dortmund, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 7 patents to his name, his work focuses on innovative solutions for treating various disorders.

Latest Patents

One of his latest patents is titled "Quinoline derivatives as TAM RTK inhibitors." This invention relates to novel compounds that act as inhibitors of TAM (Axl, Mer, and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are particularly suitable for treating disorders associated with hyperfunction of the TAM family receptors, including hyperproliferative disorders such as cancer, especially immune-suppressive cancer, refractory cancer, and cancer metastases. Another significant patent is for "4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group." This invention involves compounds that can be used for the treatment and prophylaxis of hyper-proliferative disorders, virally induced infectious diseases, and cardiovascular diseases.

Career Highlights

Throughout his career, Carsten has worked with prominent organizations such as Lead Discovery Center GmbH and Bayer Intellectual Property GmbH. His experience in these companies has allowed him to refine his expertise in drug discovery and development.

Collaborations

Carsten has collaborated with notable colleagues, including Gerd Rühter and Jan Eickhoff. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Carsten Schultz-Fademrecht is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of serious medical conditions. His innovative patents reflect his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.